- Home
- KALA vs BCAB Comparison
KALA vs BCAB Comparison
Compare KALA & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- BCAB
- Stock Information
- Founded
- KALA 2009
- BCAB 2007
- Country
- KALA United States
- BCAB United States
- Employees
- KALA N/A
- BCAB N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- KALA Health Care
- BCAB Health Care
- Exchange
- KALA Nasdaq
- BCAB Nasdaq
- Market Cap
- KALA 26.2M
- BCAB 21.6M
- IPO Year
- KALA 2017
- BCAB 2020
- Fundamental
- Price
- KALA $14.65
- BCAB $0.61
- Analyst Decision
- KALA Strong Buy
- BCAB Hold
- Analyst Count
- KALA 2
- BCAB 3
- Target Price
- KALA $13.50
- BCAB $1.00
- AVG Volume (30 Days)
- KALA 205.1K
- BCAB 665.1K
- Earning Date
- KALA 08-08-2025
- BCAB 11-06-2025
- Dividend Yield
- KALA N/A
- BCAB N/A
- EPS Growth
- KALA N/A
- BCAB N/A
- EPS
- KALA N/A
- BCAB N/A
- Revenue
- KALA N/A
- BCAB $11,000,000.00
- Revenue This Year
- KALA N/A
- BCAB N/A
- Revenue Next Year
- KALA N/A
- BCAB N/A
- P/E Ratio
- KALA N/A
- BCAB N/A
- Revenue Growth
- KALA N/A
- BCAB N/A
- 52 Week Low
- KALA $2.92
- BCAB $0.24
- 52 Week High
- KALA $15.80
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- KALA 82.92
- BCAB 77.82
- Support Level
- KALA $8.50
- BCAB $0.44
- Resistance Level
- KALA $15.80
- BCAB $0.46
- Average True Range (ATR)
- KALA 1.25
- BCAB 0.04
- MACD
- KALA 0.55
- BCAB 0.02
- Stochastic Oscillator
- KALA 86.77
- BCAB 92.43
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.